Logo
Afterderm Puri PDRN

Afterderm Puri PDRN

Afterderm (Puri)

Skin Booster
  • Described by supplier as a pharmaceutical Grade polydeoxyribonucleotide solution produced under ISO 13485 Certified quality management.
  • Manufactured using patented purification technology to achieve high bioactive purity and low endotoxin levels.
  • Terminally sterilised (e.g. 121 °C for 15 minutes, as reported in supplier specifications).
  • Intended exclusively for professional use in clinical settings, in compliance with local medical and cosmetic regulations.
Injectable PDRN Skin Booster with Hyaluronic Acid

Description

Afterderm Puri PDRN (PURI PDRN 2.5ml x 5) is a professional injectable skin booster designed to enhance skin elasticity, hydration, and overall dermal quality. Branded as PURI PDRN Skin Booster by Afterderm and sold in multiple aesthetic markets, it combines pharmaceutical-grade polydeoxyribonucleotide (PDRN) with cross-linked hyaluronic acid to rejuvenate skin at a cellular level. The formulation contains 5 mg/ml of bioactive PDRN fragments (500–1500 Da) and 25 mg/ml cross-linked hyaluronic acid, creating a powerful synergy: HA delivers long-lasting moisture and plumping, while PDRN stimulates dermal regeneration, collagen synthesis, and improved tissue repair. Clinical data reported by the supplier describe increases in collagen density, reductions in wrinkle depth and pore size, and measurable improvements in skin brightness after a course of treatments. The product is supplied as 5 x 2.5 ml sterile ampoules or pre-filled injections, with some distributors offering single-injection options. It is indicated for dull, tired, and ageing skin, working at a cellular level to rejuvenate, repair, and revitalise the complexion from within.

Bnefits

  • Improves skin elasticity and firmness through PDRN-mediated collagen stimulation and dermal regeneration.
  • Delivers intense, long-lasting hydration via cross-linked hyaluronic acid, helping to relieve dryness and rough texture.
  • Helps reduce the appearance of fine lines and wrinkles by increasing dermal density and support.
  • Refines skin texture and minimises the visibility of pores for smoother-looking skin.
  • Brightens dull or tired-looking skin, contributing to more translucent and radiant tone.
  • Supports repair of photo-damaged and ageing skin by promoting cellular renewal and tissue regeneration.
  • Acts at a cellular level, with bioactive PDRN fragments designed for high uptake and regenerative activity.
  • Professional-strength formulation suitable for face and other indicated areas in clinic-based protocols.
  • Supplied in multiple ampoules (2.5 ml x 5), allowing full treatment courses from a single box.
  • Compatible with mesotherapy guns and manual injection techniques using fine-gauge needles.

Indications

  • Dull, tired, or photo-damaged facial skin requiring rejuvenation and radiance improvement.
  • Loss of elasticity and firmness in the skin due to ageing or environmental damage.
  • Fine lines and superficial to moderate wrinkles, particularly in the mid and lower face.
  • Rough or uneven skin texture and enlarged pores.
  • Skin dryness and dehydration requiring deep, long-lasting moisturisation.
  • Supportive regenerative treatment as part of a broader skin-quality improvement or anti-ageing protocol, in appropriately selected adult patients.

Composition

  • Polydeoxyribonucleotide (PDRN) 5 mg/ml (pharmaceutical-grade bioactive fragments, approximately 500–1500 Da).
  • Cross-linked hyaluronic acid 25 mg/ml.
  • Sterile aqueous buffer and excipients as specified in the manufacturer’s pharmaceutical specifications.
  • Solution is sterile, endotoxin-controlled (<2 EU/ml as reported by supplier) and protein-free at 99.8% purity.

Formulation

  • Injectable, clear or slightly opalescent solution containing PDRN and cross-linked hyaluronic acid.
  • Pharmaceutical-grade polydeoxyribonucleotide solution produced under ISO 13485 standards using patented purification technology.
  • Designed as a professional rejuvenating essence for dermal regeneration, elasticity enhancement, and moisture retention.
  • Optimised viscosity to be delivered via manual injection or mesotherapy gun using 31–34G needles at epidermal–dermal junction depths.

Packaging

  • Box containing 5 ampoules or pre-filled units, each with 2.5 ml of PURI PDRN solution (total 12.5 ml per box).
  • Some distributors (e.g. Aesthipharma) offer single packed pre-filled injections with options to purchase 1, 3, or 5 injections per order.
  • Each ampoule/syringe is supplied sterile and intended for single use only.
  • Outer carton labelled with product name (PURI PDRN / Afterderm Puri PDRN), batch/lot number, and expiry date.
  • Packaged and marketed as a professional skin booster within the ‘Skin Booster’ category.

Usage

  • For professional use only; injections must be performed by licensed healthcare or aesthetic practitioners experienced with injectable skin boosters and facial anatomy.
  • Obtain a complete medical history and assess indications, contraindications, and patient expectations prior to treatment; secure informed consent according to local regulations.
  • Cleanse and disinfect the treatment area thoroughly with an appropriate antiseptic before injection.
  • Recommended injection plane is typically at the epidermal–dermal junction or superficial to mid-dermis, using mesotherapy techniques (micro-depots, nappage, or mesogun injections) as per clinical protocol.
  • Recommended needle size from supplier protocol: 31–34G needles (including 5/9-pin mesogun needles where appropriate).
  • Typical injection depth: approximately 1.2–2.4 mm, adapted to the patient’s skin thickness and treatment area.
  • Suggested dosage according to supplier protocol: approximately 0.5–1 ml per treatment area, divided into multiple micro-injections.
  • Treatment frequency: every 2–3 weeks, with a recommended course of 4 sessions for optimal results.
  • After the initial course, maintenance treatments can be scheduled (e.g. quarterly) based on clinical response and practitioner judgment.
  • Following treatment, mild erythema and swelling may occur; advise patients to avoid makeup on treated areas for several hours and to avoid intense heat, saunas, sun exposure, or vigorous exercise for 24–48 hours.
  • All used needles and any remaining product must be discarded immediately after the session; do not reuse or share leftover product between patients.

Contraindications

  • Known hypersensitivity or allergy to PDRN (including salmon-derived nucleotides), hyaluronic acid, or any component of the formulation.
  • History of severe allergic reactions or anaphylaxis to injectable aesthetic products.
  • Active skin infection, inflammation, or disease (e.g. dermatitis, acne flare, herpes) at or near the intended injection sites.
  • Systemic infection or uncontrolled systemic illness where elective injectable treatments may pose additional risk, as determined by the treating clinician.
  • Known bleeding disorders or current significant anticoagulant/antiplatelet therapy where the risk of bleeding or haematoma cannot be adequately managed.
  • Pregnancy or breastfeeding, due to limited safety data for PDRN/PN-based injectables in these populations.
  • History of keloid formation or hypertrophic scarring in areas to be treated, unless carefully evaluated and deemed acceptable risk by a specialist.
  • Patients undergoing radiation therapy to the treatment area.
  • Patients under 18 years of age or younger than the local legal minimum for cosmetic injectable treatments.
  • Intravascular injection is strictly contraindicated; do not inject into or near known blood vessels.

Adverse Effects

  • Common transient injection-site reactions such as redness, swelling, tenderness, pain, and bruising.
  • Temporary papules or small lumps at injection points, usually resolving over several days as the product disperses.
  • Mild pruritus or warmth in the treated area shortly after injection.
  • Haematoma formation, particularly in highly vascular regions or in patients on antithrombotic medications.
  • Local infection if aseptic technique is not meticulously followed.
  • Possible hypersensitivity or allergic reactions to salmon-derived PDRN or other formulation components.
  • Rare but serious complications such as vascular occlusion, tissue ischaemia, or necrosis if accidental intravascular injection or significant vascular compression occurs.
  • Persistent oedema, prolonged erythema, or signs of inflammatory reaction should prompt clinical review and may require cessation of treatment and further management.

Storage Conditions

  • Store at room temperature as specified by the supplier (commonly in the range of approximately 2–25 °C), away from direct sunlight.
  • Do not freeze the product.
  • Keep ampoules/syringes in their original packaging until immediately before use to preserve sterility and protect from light.
  • Do not use after the expiry date printed on the packaging.
  • Do not use if the packaging, ampoule, or syringe appears damaged, previously opened, or contaminated.
  • Store out of reach of children and unauthorised persons.

Duration

Clinical improvements are typically built over a course of approximately 4 sessions at 2\u20133 week intervals, with reported benefits (e.g. improved collagen density, reduced wrinkles, refined pores, and increased brightness) lasting several months after completion. With periodic maintenance (e.g. every 3\u20136 months), many patients may maintain results for 6\u201312 months, depending on skin condition, lifestyle, and individual biological response.

Onset

Initial improvements in hydration and skin texture can be noticed within the first 1\u20132 weeks after treatment, with more pronounced changes in elasticity, wrinkle depth, pore size and brightness generally becoming evident after multiple sessions over 8\u201316 weeks as dermal regeneration progresses.

Browse more Skin Booster

Top Treatments

Top Cities in the UK